-
Mashup Score: 0Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial? - 1 year(s) ago
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was an alkalinising agent with the rationale being evidence of increased tumour exposure of MMC in alkaline pH. Randomisation was performed prior…
Source: Urology NewsCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Outcomes of sarcomatoid differentiation in urothelial carcinoma - 1 year(s) ago
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and 2018 to compare outcomes of patients with sarcomatoid histology to UC not otherwise specified (UC, NOS). One hundred and…
Source: Urology NewsCategories: Latest Headlines, UrologyTweet-
Stay informed on the latest research - 👇check out our #JournalReviews on the outcomes of sarcomatoid differentiation in urothelial carcinoma. Reviewed by Karthik Rajan: https://t.co/mcZanGrqHJ #urologynews #urothelialcarcinoma #sarcomatoiddifferentiation
-
#JournalReviews - A new clinical trial compares the effectiveness of Intravesical mitomycin C (#MMC) alone vs MMC + cytosine arabinoside in treating non-muscle-invasive bladder cancer 🔬💊💪 #BladderCancer https://t.co/oisycNvNLl #ClinicalTrial #CancerResearch